Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

In patient-derived and animal tumour models, mubritinib suppressed glioblastoma stem cells and tumour growth by targeting ...

Technical variability can have a significant impact on single-cell experiments, affecting the accuracy and reproducibility of ...